A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN) - NCT01063868-(Clinical Trial 493684)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Virginia Beach |
|
State:
|
|
VA |
| Zip Code: |
|
|
| Conditions: |
|
Diabetic Neuropathy, Painful - Diabetic Polyneuropathy |
| Purpose: |
|
The purpose of this study is to evaluate the safety profile of orally administered
tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful
diabetic peripheral neuropathy (DPN) over long-term exposure of up to 1 year.
|
| Study summary: |
|
This is a randomized, active-controlled, multicenter study evaluating the efficacy, safety,
and tolerability of orally administered tapentadol, using the extended release
tamper-resistant formulation (TRF), at dosages of 100 to 250 mg twice daily in patients with
moderate to severe pain due to chronic, painful DPN. The study consists of 1) a 13-day
screening period, a 3-7-day washout period (where patients are to stop taking their pain
medication), a 1-day pretitration pain-intensity evaluation period (where patients will
record their 24-hour pain intensity), and a 3-week, open-label titration period (patients
will receive either tapentadol ER or oxycodone CR study drug in a 3 to 1 ratio), 2) a
49-week, open-label maintenance phase, and 3) a posttreatment phase of approximately 10 to
14 days. The study will evaluate the safety and tolerability of orally administered
tapentadol ER by vital signs, physical examinations, clinical laboratory tests, 12-lead
electrocardiograms (ECGs), opioid withdrawal scales, assessment of patient-reported
constipation, standardized neurologic examinations and monitoring of adverse events.
Assessments of pain relief include the pain intensity numerical rating scale, and patient
global impression of change scale (PGIC). The total duration of study drug treatment for
each patient will be approximately 52 weeks. Titrate tapentadol ER 50 mg twice daily or
oxycodone CR 10 mg twice daily to patient's optimal dose ranging between 100 mg and 250 mg
twice daily or 20 and 50 mg twice daily, respectively. All doses of study medication will
be taken orally with or without food for a maximum timeframe of 52 weeks. |
| Criteria: |
|
Inclusion Criteria:
- Man or woman aged 18 years or older
- Patients with Type 1 or 2 diabetes mellitus must have a documented clinical diagnosis
of painful diabetic peripheral neuropathy with symptoms and signs for at least 6
months, and pain present at the time of screening
- Diagnosis must include pain plus reduction or absence of pin sensibility and/or
vibration sensibility on Total Neuropathy Score - Nurse (TNSn) examination in lower
and/or upper extremities at screening
- The investigator considers the patient's blood glucose to be controlled by diet, or
hypoglycemics, or insulin for at least 3 months prior to enrolling in the study (this
control should be documented by figures of glycated hemoglobin (HbA1c) no greater
than 11% at screening)
- Patients have been taking analgesic medications for the condition for at least 3
months prior to screening (patients taking opioid analgesics must be dissatisfied
with current treatment, and patients taking non-opioid analgesics must be
dissatisfied with current analgesia)
- Patients currently requiring opioid treatment must be taking daily doses of an
opioid-based analgesic equivalent to <=160mg of oral morphine
- Patients with baseline score for average pain intensity in the previous 24 hours of
=>4 on the 11-point numerical rating scale (NRS) at the beginning of the titration
period
Exclusion Criteria:
- Significant pulmonary, gastrointestinal, endocrine, metabolic (except diabetes
mellitus), neurological, psychiatric disorders (resulting in disorientation, memory
impairment or inability to report accurately as in schizophrenia, Alzheimer's
disease)
- History of moderate to severe hepatic impairment
- Severely impaired renal function
- Clinically significant laboratory abnormalities
- Clinically significant cardiac disease
- History of seizure disorder or epilepsy
- History of any other clinically significant disease that in the investigator's
opinion may affect efficacy or safety assessments or may compromise patient safety
during study participation. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 11, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|